Ralph Teague, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1225099385
Payments from drug & device makers
Across 1,481 payments — averaging $329.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$161K
- AstraZeneca$155K
- Novo Nordisk$73K
- Amarin Pharma, Inc.$30K
- Johnson & Johnson$17K
- Amgen$16K
- plus $36K from 44 others
What the payments were for
- Consulting fees$7,6002%
- Speaking & faculty fees$384,62879%
- Travel & lodging$69,63114%
- Food & beverage$24,7195%
- Education$2190%
- Gifts$590%
- Charitable contribution$5000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$487,356 in reported general payments places this provider in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 550 | $636,578 |
| KorlymMifepristone | 14 | $535,475 |
| OzempicSemaglutide | 374 | $495,661 |
| Tresiba Flextouch U-200Insulin Degludec | 228 | $306,373 |
| FarxigaDapagliflozin Propanediol | 334 | $289,583 |
| TrulicityDulaglutide | 255 | $283,940 |
| JardianceEmpagliflozin | 250 | $244,912 |
| RybelsusSemaglutide | 75 | $96,923 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $85,735 |
| JanuviaSitagliptin Phosphate | 71 | $80,316 |
| Tresiba Flextouch U-100Insulin Degludec | 89 | $73,933 |
| KerendiaFinerenone | 73 | $64,410 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $55,002 |
| Icosapent Ethyl | 110 | $48,472 |
| VascepaIcosapent Ethyl | 66 | $48,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $160,592 | $962,562958 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $72,663 | $628,275524 claims |
| Corcept TherapeuticsKorlym | $996 | $535,47514 claims |
| AstraZenecaFarxiga | $155,337 | $289,583334 claims |
| Boehringer IngelheimJardiance | $15,169 | $244,912250 claims |
| MerckJanuvia, Janumet | $98 | $109,454108 claims |
| BayerKerendia | $11,841 | $64,41073 claims |
| AbbVieSynthroid | $530 | $31,809429 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $693 | $19,3811,474 claims |
| Johnson & JohnsonInvokana | $16,708 | $13,29015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- William GarveyBirmingham$3.8M
- Fernando OvalleBirmingham$516K
- Amy WarrinerBirmingham$182K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Tom VaughanBirmingham$68K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Ananda BasuBirmingham$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.